MedPacto - About the company
MedPacto is a public company based in Suwon-si (South Korea), founded in 2013. It operates as a Company developing ALK-5 kinase inhibitors for treating solid tumors and multiple myeloma. MedPacto has raised $16M in funding. The company has 3359 active competitors, including 1125 funded and 781 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
MedPacto, spun-off from Theragen Etex, (a specialized genomics company) is engaged in the development of small molecules for cancer. Their lead candidate which is currently undergoing Phase 1 trials is TEW-7197, an inhibitor of ALK-5 to block signal transduction by TGF-b and TEW-0201, an inhibitor of BRAF and c-RAF, which is in the preclinical stage. TEW-7197 was originally developed by the Ewha Woman's University with government support of the Program for Disease-Based Discovery of Global New Drug Candidates and was out-licensed from Ewha to MedPacto.
- Website
- medpacto.com
- Email ID
- *****@medpacto.com
- Phone Number
- +82 **********
Key Metrics
Founded Year
2013
Location
Suwon-si, South Korea
Stage
Public
Total Funding
$16M in 2 rounds
Latest Funding Round
Investors
Ranked
341st among 3359 active competitors
Employee Count
22 as on Aug 31, 2026
Similar Companies
Exit Details
Public
MedPacto's IPO details
MedPacto got listed on Dec 19, 2019.
Click here to take a look at MedPacto's IPO in detail
Sign up to download MedPacto's company profile
MedPacto's funding and investors
MedPacto has raised a total funding of $16M over 2 rounds. Its first funding round was on 2018. MedPacto has 9 institutional investors.
Here is the list of recent funding rounds of MedPacto:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 24, 2020 | 6076593 | Post IPO | 1811307 | 1798775 | 6161713 | 2628231 |
2018 | 4300 | Series A | 5388 | 8182 | 9416 | 7917 |
Access funding benchmarks and valuations. Sign up today!View details of MedPacto's funding rounds and investors
MedPacto's founders and board of directors
Founder? Claim ProfileMedPacto's employee count trend
MedPacto has 22 employees as of Aug 26. Here is MedPacto's employee count trend over the years:
Uncover MedPacto's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
MedPacto's Competitors and alternates
Top competitors of MedPacto include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of MedPacto, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
341st | MedPacto 2013, Suwon-si (South Korea), Public | Company developing ALK-5 kinase inhibitors for treating solid tumors and multiple myeloma | $16M | 56/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on MedPacto's competitors? Click here to see the top ones
MedPacto's Investments and acquisitions
MedPacto has made no investments or acquisitions yet.
Reports related to MedPacto
Here is the latest report on MedPacto's sector:
News related to MedPacto
Filter this listMedia has covered MedPacto for 1 event in last 1 year.
•
MedPacto's Cancer Drug Candidate Selected for National New Drug Projectmk.co.kr•Nov 20, 2025•MedPacto
•
Chime Biologics, MedPacto Partner to Accelerate Biologics Development & ManufacturingContract Pharma•Oct 28, 2024•Chime Biologics, MedPacto
•
•
•
•
MedPacto's anti-cancer substance designated as US FDA fast-track itemKedglobal•Jan 18, 2023•MedPacto
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about MedPacto
Explore our recently published companies
- Robert Hunecke - 2007 founded, Unfunded company
- K4 Makeready - Houston based, 2008 founded, Unfunded company
- MIST OF MIAMI INSULATION - United Arab Emirates based, 1987 founded, Unfunded company
- Nexus and Nexus - Unfunded company
- Silage Agro - Patiala based, 2014 founded, Seed company
- Densix - Oxford based, 2025 founded, Seed company
